# SLAMF7 (CS1)

Source: https://onco.cc/targets/slamf7/  
OnCo record `slamf7` (Target). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A surface protein found on myeloma cells and on natural killer cells. Elotuzumab tags myeloma cells with it while also switching on the natural killer cells that carry it.

## Summary

SLAMF7, also known as CS1 or CD319, is a signalling lymphocyte activation molecule family receptor expressed at high levels on malignant plasma cells and on natural killer cells, with little expression on other normal tissues. Elotuzumab, a humanised antibody against SLAMF7, marks myeloma cells for antibody-dependent cellular cytotoxicity and directly activates natural killer cells through the same receptor. It has no single-agent activity but improves outcomes with lenalidomide or pomalidomide plus dexamethasone, the basis of its 2015 and 2018 approvals.

## Fields

- Kind: Target
- Last checked: 2026-09-04
- Symbol: SLAMF7
- Class: surface-antigen
- Biology: SLAM family receptor signalling through EAT-2 in natural killer cells; highly expressed on plasma cells and myeloma cells.
- Where found: Multiple myeloma (near-universal expression on malignant plasma cells)

## Sources

- Wikipedia: https://en.wikipedia.org/wiki/SLAMF7
- UniProt Q9NQ25: SLAMF7: https://www.uniprot.org/uniprotkb/Q9NQ25/entry

## Connected records

- cancers: [Multiple myeloma](https://onco.cc/cancers/multiple-myeloma/)
- drugs: [Elotuzumab](https://onco.cc/drugs/elotuzumab/)
- terms: [ADCC (antibody-dependent cellular cytotoxicity)](https://onco.cc/terms/adcc/)

---
JSON: https://onco.cc/api/v1/entities/slamf7.json